Tranquis Therapeutics: Funding, Investors & Team (Oct 2026)
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.
Tranquis Therapeutics has raised $30.0M across 1 funding round on record, the most recent an undisclosed round of $30.0M announced in Jul 2020.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tranquis Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2020.
Tranquis Therapeutics Funding Rounds
Tranquis Therapeutics Founders and Leadership Team
Contact details for the Tranquis Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Tranquis Therapeutics Funding Compared to Other Biotechnology Startups
Tranquis Therapeutics' latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tranquis Therapeutics in Biotechnology and San Mateo
Companies Similar to Tranquis Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Tranquis Therapeutics Funding FAQs
What does Tranquis Therapeutics do?
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.
How much funding has Tranquis Therapeutics raised?
Tranquis Therapeutics has raised $30.0M across 1 round on record. The most recent is an undisclosed round of $30.0M announced in Jul 2020.
When did Tranquis Therapeutics last raise funding?
Tranquis Therapeutics' most recent funding round on record is an undisclosed round of $30.0M, announced in Jul 2020.
Who is the CEO of Tranquis Therapeutics?
Sanjay Kakkar is listed as CEO at Tranquis Therapeutics.
Where is Tranquis Therapeutics headquartered?
Tranquis Therapeutics is based in San Mateo, California, United States.
How many employees does Tranquis Therapeutics have?
Tranquis Therapeutics is in the 1-10 employee band.
How does Tranquis Therapeutics' funding compare to other Biotechnology startups?
Tranquis Therapeutics' latest round of $30.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Tranquis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tranquis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.